Literature DB >> 25772076

Reversible splenial lesion and complex visual disturbances due to carbamazepine withdrawal.

Rosa Cortese1, Giuseppe Pontrelli, Maria Paola Mogavero, Franca Dicuonzo, Carla Tortorella.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25772076     DOI: 10.1007/s10072-015-2144-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  5 in total

1.  Sympathomimetic-induced kaleidoscopic visual illusion associated with a reversible splenium lesion.

Authors:  Heather Winslow; Bruce Mickey; Elliot M Frohman
Journal:  Arch Neurol       Date:  2006-01

Review 2.  Visual interhemispheric communication and callosal connections of the occipital lobes.

Authors:  Giovanni Berlucchi
Journal:  Cortex       Date:  2013-02-13       Impact factor: 4.027

Review 3.  Reversible splenial lesion syndrome (RESLES): what's in a name?

Authors:  Juan Carlos Garcia-Monco; Ines Escalza Cortina; Eva Ferreira; Amaia Martínez; Lara Ruiz; Alberto Cabrera; Marian Gomez Beldarrain
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

Review 4.  Systemic therapies for inflammatory eye disease: past, present and future.

Authors:  Alastair K Denniston; Andrew D Dick
Journal:  BMC Ophthalmol       Date:  2013-04-24       Impact factor: 2.209

Review 5.  The corpus callosum and the visual cortex: plasticity is a game for two.

Authors:  Marta Pietrasanta; Laura Restani; Matteo Caleo
Journal:  Neural Plast       Date:  2012-06-21       Impact factor: 3.599

  5 in total
  2 in total

1.  Reversible lesion involving the splenium of the corpus callosum caused by phenytoin sodium withdrawal.

Authors:  Lingling Wang; Xiaoshan Wang; Xiangsong Shi; Wenchao Qiu; Ailiang Miao
Journal:  Neurol Sci       Date:  2016-11-19       Impact factor: 3.307

2.  Reversible splenial lesion syndrome due to oxcarbazepine withdrawal: case report and literature review.

Authors:  Chaoyang Jing; Lichao Sun; Zhuo Wang; Chaojia Chu; Weihong Lin
Journal:  J Int Med Res       Date:  2018-01-11       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.